We validated this association in vitro using four CREBBP mutated and four wild-type SCLC cell lines and two PLK1 inhibitors (Volasertib and BI2536), confirming that the effect of PLK1 inhibitors depended on the mutational status of CREBBP. Besides, we further validated DrugSniper in-silico in tumor types different from SCLC, focusing on several known personalized treatments, including the sensitivity of Olaparib in BRCA mutant patients and to Vemurafenib in BRAF mutant cells. The gene discussed is BRAF; the disease is small cell lung carcinoma.